Cited by 432Liver physiology and pathologyLiver Disease Diagnosis and TreatmentLiver Disease and Transplantation

The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index, and 1 are not checked yet.

Hepatic fibrosis 2022: Unmet needs and a blueprint for the future

Open access

Friedman, Scott L., Pinzani, Massimo·2022·Hepatology

DOI 10.1002/hep.32285PMC PMC12179971

Open this paper in CoChat — free account

Abstract

Steady progress over four decades toward understanding the pathogenesis and clinical consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet none has been approved. Thus, an assessment of the field is timely, to clarify priorities and accelerate progress. Here, we highlight the successes to date but, more importantly, identify gaps and unmet needs, both experimentally and clinically. These include the need to better define cell–cell interactions and etiology‐specific elements of fibrogenesis and their link to disease‐specific drivers of portal hypertension. Success in treating viral hepatitis has revealed the remarkable capacity of the liver to degrade scar in reversing fibrosis, yet we know little of the mechanisms underlying this response. Thus, there is an exigent need to clarify the cellular and molecular mechanisms of fibrosis regression in order for therapeutics to mimic the liver’s endogenous capacity. Better refined and more predictive in vitro and animal models will hasten drug development. From a clinical perspective, current diagnostics are improving but not always biologically plausible or sufficiently accurate to supplant biopsy. More urgently, digital pathology methods that leverage machine learning and artificial intelligence must be validated in order to capture more prognostic information from liver biopsies and better quantify the response to therapies. For more refined treatment of NASH, orthogonal approaches that integrate genetic, clinical, and pathological data sets may yield treatments for specific subphenotypes of the disease. Collectively, these and other advances will strengthen and streamline clinical trials and better link histologic responses to clinical outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/hep.32285

Cites

148 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Histological grading and staging of chronic hepatitis.
Ishak, K., Baptista, A., Bianchi, L., Callea, F., Groote, J. D., Gudat, F., Denk, H., Desmet, V., Korb, G., Macsween, R. N., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,290
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citation
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bédossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,107
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Self-citation
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
MacParland, S. A., Liu, J. C., Ma, X.-Z., Innes, B. T., Bartczak, A. M., Gage, B. K., Manuel, J., Khuu, N., Echeverri, J., Linares, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06318-7 · Cited by 1,552
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Self-citation
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424

Flagged first, then by citations

Show all 147 references

Research works printed but not linked: 3

1970, Hepatic fibrosis. Correlation of biochemical and morphologic investigations, Am J Med, 49, 707
2021, The Tabula Sapiens: a single cell transcriptomic atlas of multiple organs from individual human donors, bioRxiv
2020, Why do so many NASH trials fail?, Gastroenterology

Sorted by citations

Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 239
Self-citation
Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases
Wang, Y., Hu, J., Wu, S., Fleishman, J. S., Li, Y., Xu, Y.-S., Zou, W., Wang, J., Feng, Y., Chen, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01720-0 · Cited by 225
Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
The Evolution of Single-Cell RNA Sequencing Technology and Application: Progress and Perspectives
Wang, S., Sun, S.-T., Zhang, X., Ding, H.-R., Yu, Y., He, J., Wang, M.-S., Yang, B., & Li, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032943 · Cited by 183
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Lurje, I., Gaisa, N. T., Weiskirchen, R., & Tacke, F. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101191 · Cited by 152
Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis
Shan, L., Wang, F., Zhai, D., Meng, X., Liu, J., & Lv, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114472 · Cited by 140
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Nogueira, J. P., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0013 · Cited by 132
MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization
Zhang, J., Liu, Y., Chen, H., Yuan, Q., Wang, J., Niu, M., Hou, L., Gu, J., & Zhang, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04802-z · Cited by 116
MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming
Mabire, M., Hegde, P., Hammoutene, A., Wan, J., Caër, C., Sayegh, R. A., Cadoux, M., Allaire, M., Weiss, E., Thibault-Sogorb, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37453-5 · Cited by 93
In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
Lee, Y., & Seki, E. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.05.010 · Cited by 102
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
Kendall, T. J., Jimenez-Ramos, M., Turner, F., Ramachandran, P., Minnier, J., McColgan, M. D., Alam, M., Ellis, H., Dunbar, D. R., Kohnen, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02602-2 · Cited by 92
Pathophysiology and therapeutic options for cirrhotic portal hypertension
Guixé‐Muntet, S., Quesada‐Vázquez, S., & Gracia‐Sancho, J. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00438-7 · Cited by 91
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications
Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 76
The Origin and Fate of Liver Myofibroblasts
Kim, H. Y., Sakane, S., Eguileor, A., Carvalho Gontijo Weber, R., Lee, W., Liu, X., Lam, K., Ishizuka, K., Rosenthal, S. B., Diggle, K., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.008 · Cited by 63
Targeting the liver clock improves fibrosis by restoring TGF-β signaling
Crouchet, É., Dachraoui, M., Jühling, F., Roehlen, N., Oudot, M. A., Durand, S., Ponsolles, C., Gadenne, C., Heydmann, L., Moehlin, J., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.034 · Cited by 66
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines
Gong, L., Wei, F., Gonzalez, F. J., & Li, G. (2023) · Hepatology · doi:10.1097/hep.0000000000000182 · Cited by 61
Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study
Kimura, K., Kanto, T., Shimoda, S., Harada, K., Kimura, M., Nishikawa, K., Imamura, J., Ogawa, E., Saio, M., Ikura, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104069 · Cited by 57
Extracellular vesicles: emerging roles, biomarkers and therapeutic strategies in fibrotic diseases
Zhu, J., Wang, S., Yang, D., Xu, W., & Qian, H. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01921-3 · Cited by 61
A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions
Yang, M., Wang, J., Xiao, W., & Fan, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1410668 · Cited by 61
The role of N-glycosylation modification in the pathogenesis of liver cancer
Hu, M., Zhang, R., Yang, J., Zhao, C., Liu, W., Huang, Y., Lyu, H., Xiao, S., Guo, D. S., Zhou, C., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05733-z · Cited by 53
Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges
Luangmonkong, T., Parichatikanond, W., & Olinga, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115740 · Cited by 55
The current landscape of antifibrotic therapy across different organs: A systematic approach
Fuster‐Martínez, I., & Calatayud, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107245 · Cited by 60
Fibroblasts in liver cancer: functions and therapeutic translation
Affo, S., Filliol, A., Gores, G. J., & Schwabe, R. F. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00111-5 · Cited by 49
Single-cell and spatially resolved transcriptomics for liver biology
Lin, P., Yan, X., Jing, S., Wu, Y., Shan, Y., Guo, W., Gu, J., Li, Y., Zhang, H., & Li, H. (2023) · Hepatology · doi:10.1097/hep.0000000000000387 · Cited by 56
Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis
Zhang, L., Deng, W., Huang, Q., Zhang, J., Wang, Y., Zhou, T., Xing, L., & Jiang, H. (2024) · Advanced Materials · doi:10.1002/adma.202311474 · Cited by 48
Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models
Caon, E., Martins, M. C., Hodgetts, H., Blanken, L., Vilia, M. G., Levi, A., Thanapirom, K., Al‐Akkad, W., Abu‐Hanna, J., Baselli, G., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.032 · Cited by 45
Self-citation
Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress
Blas‐García, A., & Apostolova, N. (2023) · Antioxidants · doi:10.3390/antiox12081567 · Cited by 51
DNA 5mC and RNA m6A modification successively facilitates the initiation and perpetuation stages of HSC activation in liver fibrosis progression
Feng, Y. M., Guo, S., Zhao, Y., Dong, H., Qian, J., Hu, Y., Wu, L., Jia, Y., & Zhao, R. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01130-3 · Cited by 46
Insights into the impact of hepatitis B virus on hepatic stellate cell activation
You, H., Wang, X., Ma, L., Zhang, F., Zhang, H., Wang, Y., Pan, X., Zheng, K., Kong, F., & Tang, R. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01091-7 · Cited by 50
Emodin promotes hepatic stellate cell senescence and alleviates liver fibrosis via a nuclear receptor (Nur77)‐mediated epigenetic regulation of glutaminase 1
Chen, L., Liang, B., Xia, S., Wang, F., Li, Z., Shao, J., Zhang, Z., Chen, A., Zheng, S., & Zhang, F. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16156 · Cited by 42
Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice
Yao, Z., Gong, Y., Chen, W., Shao, S., Song, Y., Guo, H., Li, Q., Liu, S., Wang, X., Zhang, Z., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00896-7 · Cited by 48
Extracellular matrix turnover: phytochemicals target and modulate the dual role of matrix metalloproteinases ( MMPs ) in liver fibrosis
Sabir, U., Gu, H., & Zhang, D. (2023) · Phytotherapy Research · doi:10.1002/ptr.7959 · Cited by 40
3D Bioprinting: An Important Tool for Tumor Microenvironment Research
Li, Y., Liu, J., Xu, S. Q., & Wang, J. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s435845 · Cited by 40
Hydronidone for the Treatment of Liver Fibrosis Related to Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial
Cai, X., Liu, X., Xie, W., Ma, A., Tan, Y., Shang, J., Zhang, J., Chen, C., Yu, Y., Qu, Y., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.056 · Cited by 39
Galectin-3: therapeutic targeting in liver disease
MacKinnon, A. C., Tonev, D., Jacoby, B., Pinzani, M., & Slack, R. J. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2258280 · Cited by 39
Self-citation
Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
Kram, M. T. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i2.201 · Cited by 39
Resident macrophages of the lung and liver: The guardians of our tissues
Kulle, A., Thanabalasuriar, A., Cohen, T. S., & Szydlowska, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029085 · Cited by 43
A FAPα-activated MRI nanoprobe for precise grading diagnosis of clinical liver fibrosis
Gao, J., Wang, Y., Meng, X., Wang, X., Han, F., Xing, H., Lv, G., Zhang, L., Wu, S., Jiang, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52308-3 · Cited by 38
Curcumin Alleviates Aflatoxin B1-Induced Liver Pyroptosis and Fibrosis by Regulating the JAK2/NLRP3 Signaling Pathway in Ducks
Cui, Y., Wang, Q., Zhang, X., Yang, X., Shi, Y., Li, Y., & Song, M. (2023) · Foods · doi:10.3390/foods12051006 · Cited by 36
Glycolysis in Chronic Liver Diseases: Mechanistic Insights and Therapeutic Opportunities
Qu, H., Liu, J., Zhang, D., Xie, R., Wang, L., & Hong, J. (2023) · Cells · doi:10.3390/cells12151930 · Cited by 36
The Material World of 3D‐Bioprinted and Microfluidic‐Chip Models of Human Liver Fibrosis
Carvalho, A. M., Bansal, R., Barrias, C. C., & Sarmento, B. F. C. C. (2023) · Advanced Materials · doi:10.1002/adma.202307673 · Cited by 36
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 45
Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis
Kong, M., Zhou, J., Kang, A., Kuai, Y., Xu, H., Li, M., Miao, X., Guo, Y., Fan, Z., Xu, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-329671 · Cited by 37
CCAAT/Enhancer-Binding Proteins in Fibrosis: Complex Roles Beyond Conventional Understanding
Wang, L., Feng, J., Deng, Y., Yang, Q., Wei, Q., Ye, D., Rong, X., & Guo, J. (2022) · Research · doi:10.34133/2022/9891689 · Cited by 35
Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality
Ballestri, S., Mantovani, A., Girolamo, M. D., Baldelli, E., Capitelli, M., & Lonardo, A. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.23 · Cited by 33
USP9X-mediated NRP1 deubiquitination promotes liver fibrosis by activating hepatic stellate cells
Zhao, J., Bai, J., Peng, F., Qiu, C., Li, Y., & Zhong, L. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05527-9 · Cited by 36
Diagnosis of Liver Fibrosis Using Artificial Intelligence: A Systematic Review
Popa, S., Ismaiel, A., Abenavoli, L., Padureanu, A. M., Dita, M. O., Bolchis, R., Munteanu, M. A., Brata, V. D., Pop, C., Bosneag, A., et al. (2023) · Medicina · doi:10.3390/medicina59050992 · Cited by 33
Inulin-like polysaccharide ABWW may impede CCl4 induced hepatic stellate cell activation through mediating the FAK/PI3K/AKT signaling pathway in vitro & in vivo
Dai, X., Du, Z., Jin, C., Tang, B., Chen, X., Jing, X., Shen, Y., He, F., Wang, S., Li, J., et al. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121637 · Cited by 35
Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review)
Gao, J.-Q., Zuo, B., & He, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13164 · Cited by 37
Therapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 32
Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis
Mallet, M., Silaghi, C. A., Sultanik, P., Conti, F., Rudler, M., Ratziu, V., Thabut, D., & Pais, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000456 · Cited by 31
Bile acids metabolism involved in the beneficial effects of Danggui Shaoyao San via gut microbiota in the treatment of CCl4 induced hepatic fibrosis
Zhao, Y., Zhao, M., Zhang, Y., Fu, Z., Jin, T., Song, J., Huang, Y., Zhao, C., & Wang, M. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117383 · Cited by 30
Placenta mesenchymal stem cell-derived extracellular vesicles alleviate liver fibrosis by inactivating hepatic stellate cells through a miR-378c/SKP2 axis
Zheng, W., Bian, S., Qiu, S., Bishop, C. E., Wan, M., Xu, N., Sun, X., Sequeira, R. C., Atala, A., Gu, Z., et al. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00297-z · Cited by 31
Carbon Nitride‐Based siRNA Vectors with Self‐Produced O2 Effects for Targeting Combination Therapy of Liver Fibrosis via HIF‐1α‐Mediated TGF‐β1/Smad Pathway
Liu, M., Xu, L., Cai, Y., Wang, R., Gu, Y., Liu, Y., Zou, Y., Zhao, Y., Chen, J., & Zhang, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301485 · Cited by 28
Mechanisms of liver fibrosis in metabolic syndrome
Mehal, W. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100015 · Cited by 28
Selectivity matters: selective ROCK2 inhibitor ameliorates established liver fibrosis via targeting inflammation, fibrosis, and metabolism
Zanin‐Zhorov, A., Chen, W., Moretti, J., Nyuydzefe, M. S., Zhorov, I., Munshi, R., Ghosh, M., Serdjebi, C., MacDonald, K. P. A., Blazar, B. R., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05552-0 · Cited by 29
Oxidative stress promotes liver fibrosis by modulating the microRNA-144 and SIN3A-p38 pathways in hepatic stellate cells
Hao, Y., Song, S., Li, T., Zai, Q., Ma, N., Li, Y., Liu, Y., Xiao, P., Xu, T., Ji, L., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.92749 · Cited by 28
Eupatilin Ameliorates Hepatic Fibrosis and Hepatic Stellate Cell Activation by Suppressing β-catenin/PAI-1 Pathway
Hu, J., Liu, Y., Pan, Z., Huang, X., Wang, J., Cao, W., & Chen, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065933 · Cited by 30
Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid
Wu, K., Liu, Y., Xia, J. L., Liu, J., Wang, K., Liang, H., Xu, F., Liu, D., Nie, D., Tang, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202304408 · Cited by 27
Danggui Shaoyao San: Chemical characterization and inhibition of oxidative stress and inflammation to treat CCl4-induced hepatic fibrosis
Zhao, Y., Zhao, M., Wang, Z., Zhao, C., Zhang, Y., & Wang, M. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116870 · Cited by 27
Noninvasive assessment of hepatic decompensation
Thiele, M. S., Johansen, S., Israelsen, M. E., Trebicka, J., Abraldeṣ, J. G., Ginès, P., & Krag, A. A. (2023) · Hepatology · doi:10.1097/hep.0000000000000618 · Cited by 27
Emerging targets for therapy in ALD: Lessons from NASH
Singal, A. K., Shah, V. H., & Malhi, H. (2023) · Hepatology · doi:10.1097/hep.0000000000000381 · Cited by 26
Wuling capsule modulates macrophage polarization by inhibiting the TLR4-NF-κB signaling pathway to relieve liver fibrosis
Ren, S., Zhou, R., Tang, Z., Song, Z., Li, N., Shi, X., Liu, Y., & Chu, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111598 · Cited by 26
An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis
Jackson, J., Streich, F. C., Pal, A., Coricor, G., Boston, C., Brueckner, C., Canonico, K., Chapron, C., Cote, S. M., Dagbay, K. B., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adn6052 · Cited by 30
Iron chelation as a new therapeutic approach to prevent senescence and liver fibrosis progression
Amengual, J., Alay, A., Vaquero, J., Gonzalez‐Sanchez, E., Bertrán, E., Sánchez, A., Herrera, B. M., Meyer, K. R., Maus, M., Serrano, M., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07063-0 · Cited by 27
Mitochondrial general control of amino acid synthesis 5 like 1 promotes nonalcoholic steatohepatitis development through ferroptosis‐induced formation of neutrophil extracellular traps
Lv, T., Xiong, X., Yan, W., Liu, M., Xu, H., & He, Q. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1325 · Cited by 26
Cellular senescence primes liver fibrosis regression through Notch‐EZH2
Song, P., Duan, J., Ding, J. H., Liu, J., Fang, Z., Xu, H., Li, Z., Du, W., Xu, M., Ling, Y., et al. (2023) · MedComm · doi:10.1002/mco2.346 · Cited by 25
Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis
Ding, C., Wang, Z., Dou, X., Yang, Q., Ning, Y., Kao, S., Sang, X., Hao, M., Wang, K., Peng, M., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0830 · Cited by 29
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
Ramos, M. J., Kendall, T. J., Drozdov, I. A., & Fallowfield, J. A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101278 · Cited by 26
Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
Xu, Y., Zhou, X., Wang, X., Jin, Y., Zhou, L., & Ye, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116848 · Cited by 25
Proanthocyanidins attenuated liver damage and suppressed fibrosis in CCl4-treated rats
Amer, M. A., Othman, A. I., El-Missiry, M. A., Farag, A. A., & Amer, M. E. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22051-7 · Cited by 28
MicroRNA-223 Suppresses Human Hepatic Stellate Cell Activation Partly via Regulating the Actin Cytoskeleton and Alleviates Fibrosis in Organoid Models of Liver Injury
Ariyachet, C., Chuaypen, N., Kaewsapsak, P., Chantaravisoot, N., Jindatip, D., Potikanond, S., & Tangkijvanich, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169380 · Cited by 26
Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis
Li, L., & Zhu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1071844 · Cited by 26
Expansion of macrophage and liver sinusoidal endothelial cell subpopulations during non-alcoholic steatohepatitis progression
Shen, Z., Shen, B., Dai, W., Zhou, C., Luo, X., Guo, Y., Wang, J., Xu, X., Sun, Z., Cai, X., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106572 · Cited by 26
Serum folate associated with nonalcoholic fatty liver disease and advanced hepatic fibrosis
Chen, H., Luo, J., Li, X., Liao, W., Hu, Y., & Guo, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-39641-1 · Cited by 25
Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events
Sun, Y., Chen, W., Chen, S., Wu, X., Zhang, X., Zhang, L., Zhao, H., Xu, M., Chen, Y., Piao, H., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.11.017 · Cited by 24
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications
Bai, W., & Zhu, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1720780 · Cited by 34
Modelling fatty liver disease with mouse liver-derived multicellular spheroids
van Os, E. A., Cools, L., Eysackers, N., Szafranska, K., Smout, A., Verhulst, S., Reynaert, H., McCourt, P., Mannaerts, I., & van Grunsven, L. A. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121817 · Cited by 25
Supramolecular Nanoarchitectonics Based on Antagonist Peptide Self‐Assembly for Treatment of Liver Fibrosis
Li, B., Huang, Y., Bao, J., Xu, Z., Yan, X., & Zou, Q. (2023) · Small · doi:10.1002/smll.202304675 · Cited by 24
lncRNA Helf promotes hepatic inflammation and fibrosis by interacting with PTBP1 to facilitate PIK3R5 mRNA stabilization
Han, X., Guo, B., Zhao, S., Li, Y., Zhu, J., He, Y., Wang, J., Yao, Q., Shao, S., Zheng, L., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00492-3 · Cited by 24
Astilbin alleviates hepatic fibrosis through PXR-PINK1/Parkin pathway: A new strategy by regulating hepatic stellate cells-macrophage crosstalk
Dou, J.-Y., Zhou, M.-J., Xuan, M., Guo, J., Liu, S.-H., Lian, L., Cui, Z., Nan, J., & Wu, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156144 · Cited by 23
Circularized Supramolecular Spherical Nucleic Acids Alleviates Liver Fibrosis through Blocking Upstream Activation and Reversing Activation State of Hepatic Stellate Cells
Xu, Y., Fan, Y., Zhao, Z., Hu, W., Qian, Y., & Hu, Y. M. (2025) · ACS Nano · doi:10.1021/acsnano.4c15562 · Cited by 23
Naringin ameliorates liver fibrosis in zebrafish by modulating IDO1-mediated lipid metabolism and inflammatory infiltration
Qin, M., Li, J., Zheng, Y.-T., Li, Y.-J., Zhang, Y., Ou, R.-X., He, W.-Y., Zhao, J.-M., Liu, S.-T., Liu, M., et al. (2023) · Food & Function · doi:10.1039/d3fo03858k · Cited by 22
Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13191650 · Cited by 22
Macrophage membrane-coated NIR light-photodegradable carbon nitride-based gene vectors for gas-gene therapy of liver fibrosis
Liu, M., Zhu, Y.-Q., Yang, Y., Zhang, S., Zhou, M.-Z., Wu, W., Tao, Y.-T., Liu, Y.-H., Yang, Y., & Zhang, X. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123503 · Cited by 23
Dietary linoleic acid and the ratio of unsaturated to saturated fatty acids are inversely associated with significant liver fibrosis risk: A nationwide survey
Zhu, T., Lu, X., Liu, Z.-Y., & Zhu, H. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.938645 · Cited by 24
New discoveries in the field of metabolism by applying single-cell and spatial omics
Xie, B., Gao, D., Zhou, B., Chen, S., & Wang, L. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.06.002 · Cited by 21
Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β
Wegrzyniak, O., Zhang, B., Rokka, J., Rosestedt, M., Mitran, B., Cheung, P., Puuvuori, E., Ingvast, S., Persson, J., Nordström, H., et al. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00210-6 · Cited by 21
Research Progress on Natural Products Alleviating Liver Inflammation and Fibrosis via NF‐κB Pathway
Li, X., Li, S., & Li, N. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402248 · Cited by 22
Engineered Hydrogels for Organoid Models of Human Nonalcoholic Fatty Liver Disease
Liu, Y., Gilchrist, A. E., Johansson, P. K., Guan, Y., Deras, J. D., Liu, Y., Ceva, S., Huang, M. S., Navarro, R. S., Enejder, A. M. K., et al. (2025) · Advanced Science · doi:10.1002/advs.202417332 · Cited by 22
Preparation of Betulinic Acid Galactosylated Chitosan Nanoparticles and Their Effect on Liver Fibrosis
Wu, Z. C., Liu, X. Y., Liu, J. Y., Piao, J. S., & Piao, M. G. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s373430 · Cited by 20
Peptide‐Based Nanoarchitectonics for the Treatment of Liver Fibrosis
Li, B., Huang, Y., & Zou, Q. (2023) · ChemBioChem · doi:10.1002/cbic.202300002 · Cited by 22
Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD
Herranz, J. M., López-Pascual, A., Clavería-Cabello, A., Uriarte, I., Latasa, M. U., Irigaray-Miramon, A., Adán-Villaescusa, E., Castelló-Uribe, B., Sangro, B., Arechederra, M., et al. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00976-y · Cited by 21
Mesenchymal stem cell-derived exosomal miR-26a induces ferroptosis, suppresses hepatic stellate cell activation, and ameliorates liver fibrosis by modulating SLC7A11
Cao, Y., Yang, H., Huang, Y., Lu, J., Du, H., & Wang, B. (2024) · Open Medicine · doi:10.1515/med-2024-0945 · Cited by 20
AI‐Assisted Drug Re‐Purposing for Human Liver Fibrosis
Guan, Y., Cui, L., Inchai, J., Fang, Z., Law, J., Brito, A. A. G., Pawlosky, A., Gottweis, J., Daryin, A., Myaskovsky, A., et al. (2025) · Advanced Science · doi:10.1002/advs.202508751 · Cited by 25
Research Progress Regarding the Effect and Mechanism of Dietary Polyphenols in Liver Fibrosis
Chang, J., Huang, C., Li, S., Jiang, X., Chang, H., & Li, M. (2023) · Molecules · doi:10.3390/molecules29010127 · Cited by 20
Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk
Martins, M. C., Dixon, E. D., Lupo, G., Claudel, T., Trauner, M., & Rombouts, K. (2024) · Liver International · doi:10.1111/liv.16117 · Cited by 22
Mesenchymal stem cell-derived exosomes as cell-free therapeutics: mechanistic insights and engineering strategies for liver disease treatment
Yu, S., Kong, D., Lu, B., Pan, Y., Zeng, Z., Fu, Y., Zhao, Z., He, K., Tang, R., & Xia, Q. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04747-y · Cited by 23
Dihydrokaempferol attenuates CCl4-induced hepatic fibrosis by inhibiting PARP-1 to affect multiple downstream pathways and cytokines
Huang, H., Wei, S., Wu, X., Zhang, M., Zhou, B., Huang, D., & Dong, W. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116438 · Cited by 18

Authors: Friedman, S. L., & Pinzani, M.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
University College London (GB)
Corresponding author: Friedman, Scott L.
Pinzani, Massimo
ORCID: Friedman, Scott L.
Pinzani, Massimo
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2022-01-11
Volume: 75
Issue: 2
Pages: 473-488
ISSN: 0270-9139 (ISSN-L)
1527-3350
DOI: 10.1002/hep.32285
PMC: PMC12179971
OpenAlex: W4200351549
Cited by: 430
References: 147
Citations by year: 2026: 83 · 2025: 76 · 2024: 104 · 2023: 129 · 2022: 37
FWCI: 8.85
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: National Institute of Diabetes and Digestive and Kidney Diseases (R01DK128289)
Topics: Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords: liver fibrosis, antifibrotic agents, fibrogenesis, portal hypertension, fibrosis regression, viral hepatitis, liver regeneration, fibrosis diagnosis, liver biopsy, digital pathology, machine learning, artificial intelligence, nonalcoholic steatohepatitis, clinical trials
MeSH terms: Drug Development, Antifibrotic Agents, Animals, Clinical Trials as Topic, Fibrosis, Humans, Liver, Liver Cirrhosis, Needs Assessment, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatic fibrosis 2022: Unmet needs and a blueprint for the future

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks